Effects of a Cardiac Rehabilitation Program on Hypertensive Patients with Rheumatoid Arthritis
The Effects of 6-week Cardiac Rehabilitation Programme on Cardiovascular Disease Risk, Systolic and Diastolic Blood Pressure and Disease Activity in Hypertensive Rheumatoid Arthritis Patients : A Randomised Controlled Trial
This study tests if a 6-week heart rehab program can help people with rheumatoid arthritis and high blood pressure feel better and lower their heart risks.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Sex | All |
| Sponsor | Kayseri City Hospital Government |
| Locations | 1 site (Kayseri, Kocasinan) |
| Trial ID | NCT06295848 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of a 6-week standardized cardiac rehabilitation (CR) program on patients with rheumatoid arthritis (RA) who also have hypertension. Participants will be randomly assigned to receive either standard care or standard care plus the CR program. The aim is to assess the potential benefits of exercise and lifestyle changes in managing cardiovascular risks associated with RA and hypertension. The study focuses on patients whose RA is under control with pharmacological treatment, addressing a significant gap in cardiovascular risk management for these patients.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with rheumatoid arthritis and hypertension who are receiving regular treatment.
Not a fit: Patients with severe mental disorders, unstable cardiac conditions, or other significant health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly reduce cardiovascular risks and improve overall health outcomes for patients with rheumatoid arthritis and hypertension.
How similar studies have performed: While there is limited data on similar interventions specifically for RA patients, exercise and rehabilitation programs have shown positive outcomes in managing cardiovascular risks in other chronic conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients diagnosed with RA according to ACR/EULAR 2010 criteria 2. Taking regular treatment for at least 1 month according to ACR/EULAR guidelines 3. Patients diagnosed with HT according to the 2018 European Society of Hypertension and European Society of Cardiology (ESH/ESC) guideline Exclusion Criteria: 1. Refusing to participate in the program 2. Severe mental disorder 3. Neurological disease or deformity in the lower extremity that would prevent the patient from using the treadmill. 4. High-risk unstable angina and all acute cardiac diseases (acute myocardial infarction, acute endocarditis, myocarditis or pericarditis) 5. Uncontrolled HT, Diabetes, cardiac arrhythmia and heart failure 6. Symptomatic severe aortic stenosis 7. Acute pulmonary embolism or pulmonary infarction and severe pulmonary hypertension
Where this trial is running
Kayseri, Kocasinan
- Health Sciences University, Kayseri Medicine Faculty — Kayseri, Kocasinan, Turkey (Recruiting)
Study contacts
- Principal investigator: Abdurrahman KUTLUCA, MD — Health Sciences University, Kayseri Medical Faculty
- Study coordinator: Havva Talay Çaliş, Professor
- Email: htalaycalis@yahoo.com
- Phone: +905326874541
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.